title: Opposite effects of stimulant and antipsychotic drugs on striatal fast-spiking interneurons.
abstract: Psychomotor stimulants and typical antipsychotic drugs have powerful but opposite effects on mood and behavior, largely through alterations in striatal dopamine signaling. Exactly how these drug actions lead to behavioral change is not well understood, as previous electrophysiological studies have found highly heterogeneous changes in striatal neuron firing. In this study, we examined whether part of this heterogeneity reflects the mixture of distinct cell types present in the striatum, by distinguishing between medium spiny projection neurons (MSNs) and presumed fast-spiking interneurons (FSIs), in freely moving rats. The response of MSNs to both the stimulant amphetamine (0.5 or 2.5 mg/kg) and the antipsychotic eticlopride (0.2 or 1.0 mg/kg) remained highly heterogeneous, with each drug causing both increases and decreases in the firing rate of many MSNs. By contrast, FSIs showed a far more uniform, dose-dependent response to both drugs. All FSIs had decreased firing rate after high eticlopride. After high amphetamine most FSIs increased firing rate, and none decreased. In addition, the activity of the FSI population was positively correlated with locomotor activity, whereas the MSN population showed no consistent response. Our results show a direct relationship between the psychomotor effects of dopaminergic drugs and the firing rate of a specific striatal cell population. Striatal FSIs may have an important role in the behavioral effects of these drugs, and thus may be a valuable target in the development of novel therapies.
authors.affiliation: Department of Psychology, and Neuroscience Program, University of Michigan, Ann Arbor, MI 48109-1043,, USA.
authors.forename: Alexander B
authors.initials: AB
authors.lastname: Wiltschko
authors.forename: Jeffrey R
authors.initials: JR
authors.lastname: Pettibone
authors.forename: Joshua D
authors.initials: JD
authors.lastname: Berke
mesh_terms: D000200:Action Potentials / Q000187:drug effects* / Q000502:physiology; D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology; D000697:Central Nervous System Stimulants / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004525:Efferent Pathways / Q000187:drug effects / Q000502:physiology; D007395:Interneurons / Q000187:drug effects* / Q000502:physiology; D008297:Male; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D017072:Neostriatum / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D020318:Rats, Long-Evans; D012457:Salicylamides / Q000494:pharmacology*
chemical_list: D014150:Antipsychotic Agents; D000697:Central Nervous System Stimulants; D012457:Salicylamides; D000661:Amphetamine; C045989:eticlopride